(BAS) BASF SE - Overview
Stock: Petrochemicals, Intermediates, Isocyanates, Polyamides, Fungicides
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.30% |
| Yield on Cost 5y | 4.56% |
| Yield CAGR 5y | -9.13% |
| Payout Consistency | 97.4% |
| Payout Ratio | 121.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.4% |
| Relative Tail Risk | -4.73% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -0.95 |
| Character TTM | |
|---|---|
| Beta | 0.316 |
| Beta Downside | 0.419 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.19% |
| CAGR/Max DD | 0.15 |
Description: BAS BASF SE January 28, 2026
BASF SE (XETRA:BAS) is a global chemicals leader operating across six divisions: Chemicals (petrochemicals and intermediates); Materials (advanced polymers, isocyanates, and specialty plastics); Industrial Solutions (polymer dispersions, resins, electronic materials, and antioxidants for automotive, coatings, and construction); Surface Technologies (catalysts, battery materials, automotive coatings, and metal services); Nutrition & Care (ingredients for food, pharma, cosmetics, and household products); and Agricultural Solutions (seeds, traits, crop protection chemicals, and digital farming tools). The group also generates revenue from engineering services, equipment leasing, and commodity trading.
According to the FY 2023 annual report, BASF posted €87.6 billion in revenue, a 5 % increase YoY, driven by higher demand for specialty chemicals and a modest recovery in the automotive sector. Adjusted EBITDA rose to €9.3 billion (EBITDA margin ≈ 10.6 %), while R&D spending remained steady at €2.4 billion, reflecting continued investment in high-margin specialty and digital agriculture products. A key sector driver is the ongoing volatility in energy and raw-material prices, which compresses margins in the commodity-focused Chemicals segment but creates pricing power for the higher-value Materials and Nutrition & Care divisions.
For a deeper, data-rich analysis of BASF’s valuation and risk profile, you may find ValueRay’s dedicated BASF dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 273.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -1.89 > 1.0 |
| NWC/Revenue: 25.00% < 20% (prev 22.57%; Δ 2.43% < -1%) |
| CFO/TA 0.07 > 3% & CFO 5.43b > Net Income 273.0m |
| Net Debt (20.92b) to EBITDA (7.24b): 2.89 < 3 |
| Current Ratio: 1.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (892.5m) vs 12m ago 0.0% < -2% |
| Gross Margin: 25.75% > 18% (prev 0.26%; Δ 2549 % > 0.5%) |
| Asset Turnover: 81.33% > 50% (prev 82.25%; Δ -0.92% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBITDA TTM 7.24b / Interest Expense TTM 1.14b) |
Altman Z'' 3.59
| A: 0.21 (Total Current Assets 33.09b - Total Current Liabilities 17.25b) / Total Assets 76.44b |
| B: 0.39 (Retained Earnings 29.91b / Total Assets 76.44b) |
| C: 0.03 (EBIT TTM 2.58b / Avg Total Assets 77.90b) |
| D: 0.70 (Book Value of Equity 29.62b / Total Liabilities 42.53b) |
| Altman-Z'' Score: 3.59 = A |
Beneish M -3.26
| DSRI: 0.93 (Receivables 10.26b/11.37b, Revenue 63.35b/65.27b) |
| GMI: 0.99 (GM 25.75% / 25.54%) |
| AQI: 0.87 (AQ_t 0.24 / AQ_t-1 0.28) |
| SGI: 0.97 (Revenue 63.35b / 65.27b) |
| TATA: -0.07 (NI 273.0m - CFO 5.43b) / TA 76.44b) |
| Beneish M-Score: -3.26 (Cap -4..+1) = AA |
What is the price of BAS shares?
Over the past week, the price has changed by +4.83%, over one month by +7.45%, over three months by +12.31% and over the past year by +4.97%.
Is BAS a buy, sell or hold?
What are the forecasts/targets for the BAS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.5 | 0.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 50 | 3.7% |
BAS Fundamental Data Overview February 03, 2026
P/E Trailing = 135.1765
P/E Forward = 25.1256
P/S = 0.6379
P/B = 1.2521
P/EG = 1.5324
Revenue TTM = 63.35b EUR
EBIT TTM = 2.58b EUR
EBITDA TTM = 7.24b EUR
Long Term Debt = 18.93b EUR (from longTermDebt, last quarter)
Short Term Debt = 3.85b EUR (from shortTermDebt, last quarter)
Debt = 22.78b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.92b EUR (from netDebt column, last quarter)
Enterprise Value = 61.94b EUR (41.02b + Debt 22.78b - CCE 1.86b)
Interest Coverage Ratio = 2.26 (Ebit TTM 2.58b / Interest Expense TTM 1.14b)
EV/FCF = 207.9x (Enterprise Value 61.94b / FCF TTM 298.0m)
FCF Yield = 0.48% (FCF TTM 298.0m / Enterprise Value 61.94b)
FCF Margin = 0.47% (FCF TTM 298.0m / Revenue TTM 63.35b)
Net Margin = 0.43% (Net Income TTM 273.0m / Revenue TTM 63.35b)
Gross Margin = 25.75% ((Revenue TTM 63.35b - Cost of Revenue TTM 47.04b) / Revenue TTM)
Gross Margin QoQ = 22.06% (prev 26.50%)
Tobins Q-Ratio = 0.81 (Enterprise Value 61.94b / Total Assets 76.44b)
Interest Expense / Debt = 1.16% (Interest Expense 264.0m / Debt 22.78b)
Taxrate = 29.77% (616.0m / 2.07b)
NOPAT = 1.81b (EBIT 2.58b * (1 - 29.77%))
Current Ratio = 1.92 (Total Current Assets 33.09b / Total Current Liabilities 17.25b)
Debt / Equity = 0.70 (Debt 22.78b / totalStockholderEquity, last quarter 32.76b)
Debt / EBITDA = 2.89 (Net Debt 20.92b / EBITDA 7.24b)
Debt / FCF = 70.21 (Net Debt 20.92b / FCF TTM 298.0m)
Total Stockholder Equity = 34.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.35% (Net Income 273.0m / Total Assets 76.44b)
RoE = 0.80% (Net Income TTM 273.0m / Total Stockholder Equity 34.20b)
RoCE = 4.85% (EBIT 2.58b / Capital Employed (Equity 34.20b + L.T.Debt 18.93b))
RoIC = 3.14% (NOPAT 1.81b / Invested Capital 57.66b)
WACC = 4.84% (E(41.02b)/V(63.80b) * Re(7.08%) + D(22.78b)/V(63.80b) * Rd(1.16%) * (1-Tc(0.30)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.01%
[DCF Debug] Terminal Value 83.08% ; FCFF base≈903.2m ; Y1≈686.7m ; Y5≈420.3m
Fair Price DCF = N/A (negative equity: EV 13.03b - Net Debt 20.92b = -7.90b; debt exceeds intrinsic value)
EPS Correlation: -17.85 | EPS CAGR: -38.41% | SUE: 0.07 | # QB: 0
Revenue Correlation: -85.14 | Revenue CAGR: -8.23% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.86 | Chg30d=-0.245 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=2.56 | Chg30d=-0.176 | Revisions Net=-6 | Growth EPS=-6.3% | Growth Revenue=+0.4%